

From: section 9(2)(a)
Sent: Friday, 21 February 2020 10:26 AM
To: Craig Butler; Peter Yoo
Subject: Supply chain continuity meeting - information from meeting on Tuesday
Attachments: Supply chain continuity considerations.pdf

Hi Peter and Craig,

Thank you for meeting with section 9(2)(a) and I on Tuesday to engage in a discussion with a wider MoH group about supply chain continuity for the health sector. We really appreciate your support and input into this work.

As discussed, there are four (interconnected) areas for consideration:

- current pressures on Personal Protective Equipment (PPE)
- supply chain disruption to clinical supplies
- use of National Reserve Supply (NRS)
- surge requirements in the event of a domestic COVID-19 outbreak

We have drafted a document that summarises each of these aspects, including: an overview of the issue, what needs to be considered and any action taken to date:

Prior to the follow up meeting next week we would appreciate it if you could:

- review the summary document and feed back any further considerations you think we may have missed
- advise of any other information inputs that you are aware of that may be able to inform this work.
-

At our first meeting we also spoke about the National Reserve Supply and I said I would send you the links to the relevant information. Apologies for the delay in doing this.

Here is a link to the national reserve supply composition: <https://www.health.govt.nz/our-work/emergency-management/national-reserve-supplies/composition-national-reserve-supply>

Here is a link to the usage policies: <https://www.health.govt.nz/publication/national-health-emergency-plan-national-reserve-supplies-management-and-usage-policies-3rd-edition>

We also spoke about antibiotics, and great to hear that we have good coverage of these oral antibiotics in the supply chain. I checked on the injectable antibiotics and it is my understanding that the DHBs are required to hold stock of:

- Amoxicillin Clavulanate inj. 1g vial
- Cephazolin Sodium 1g vial
- Flucloxacillin Sodium 1g vial.

Many thanks,
section 9(2)(a)

Senior Advisor - Emergency Management
Emergency Management Team
Population Health and Prevention Directorate
Ministry of Health
section 9(2)(a)

<http://www.moh.govt.nz>

section 9(2)(a)

Statement of confidentiality: This e-mail message and any accompanying attachments may contain information that is IN-CONFIDENCE and subject to legal privilege.

If you are not the intended recipient, do not read, use, disseminate, distribute or copy this message or attachments.

If you have received this message in error, please notify the sender immediately and delete this message.

This e-mail message has been scanned for Viruses and Content and cleared by the Ministry of Health's Content and Virus Filtering Gateway

RELEASED UNDER THE OFFICIAL INFORMATION ACT

From: section 9(2)(a)
Sent: Wednesday, 19 February 2020 5:47 PM
To: Peter Yoo
Cc: section 9(2)(a)
Subject: Re: Clinical advice re COVID-19

Hi Peter,

Thank you for getting in touch about this. We would be grateful if you could share the membership of your anti-infective sub-committee as a first step.

I'll follow up here at the Ministry about the latest information on pharmaceuticals for treatment of COVID-19 and get back to you as soon as possible.

Would it also be possible to send me Craig's email address? I was going to share the information from the meeting with you both but realised I only had your email address.

Regards,

section 9(2)(a)
 Senior Advisor - Emergency Management
 Emergency Management Team
 Population Health and Prevention Directorate
 Ministry of Health
 section9(2)(a)

<http://www.moh.govt.nz>

section 9(2)(a)

From: "Peter Yoo" section 9(2)(a)
 To: section 9(2)(a)
 Cc: "April-Mae Marshall" section 9(2)(a), "Gregory Evans" section 9(2)(a), "Ken Clark"
 section 9(2)(a), "Peter Murray" section 9(2)(a), "Rongo Toelupe" section 9(2)(a), "Scott Metcalfe"
 section 9(2)(a), "Sonam Naidu" section 9(2)(a), "Tristan Gardiner" section 9(2)(a), "Andrew
 Oliver" section 9(2)(a)
 Date: 19/02/2020 05:28 p.m.
 Subject: Clinical advice re COVID-19

Hi section 9(2)(a)

During our first meeting on 7 February, we mentioned that we are interested in receiving clinical advice from the Ministry of Health around managing COVID-19.

Specifically, I am looking to find out which pharmaceuticals (i.e. antivirals, antibiotics) have been identified to treat COVID-19 cases, including any related secondary infection cases such as pneumonia.

I also want to know how you think PHARMAC might be able support the NHCC in their development of this clinical advice. At our meeting section 9(2)(a) mentioned that our Anti-Infective subcommittee and relevant contact details could potentially be useful. Please let me know if you would like me to share relevant contacts with you and if there is anything else that may be helpful.

Ngā mihi

Peter Yoo | Therapeutic Group Manager | Pharmaceutical Funding
PHARMAC | PO Box 10 254 | Level 12, 40 Mercer Street, Wellington
section 9(2)(a) P: +64 4 460 4990 | F: +64 4 460 4995 | www.pharmac.govt.nz

Statement of confidentiality: This e-mail message and any accompanying attachments may contain information that is IN-CONFIDENCE and subject to legal privilege.

If you are not the intended recipient, do not read, use, disseminate, distribute or copy this message or attachments.

If you have received this message in error, please notify the sender immediately and delete this message.

This e-mail message has been scanned for Viruses and Content and cleared by the Ministry of Health's Content and Virus Filtering Gateway

RELEASED UNDER THE OFFICIAL INFORMATION ACT

From: Gillian Anderson
Sent: Tuesday, 18 February 2020 5:08 PM
To: Peter Yoo; Scott Metcalfe
Cc: Gregory Evans; Hannah Tibble-Gotz; Jane Wright; Susan Robertson
Subject: RE: Coronavirus meeting 18 Feb

Hi all,

Notes from today's meeting – I'll file it away. I'm going to be the point of contact for the Contract & Procurement Team and will be attending the meeting with the MoH next week.

Update from Peter and meeting with MoH this morning. Discussed the following items:

- MoH – new working group set up – chief med officers, pandemic response team, medsafe and Pharmac.
- PPE – MoH working with DHBs, masks produced in NZ, raw materials come from elsewhere, looking to source alternative raw materials if at risk.
- Pharmac buffer – usually 2 months buffer for medicines, currently pressure on hand sanitisers & skin prep.
- MoH actively doing modelling for mask and PPE usage – 18 million in reserve
- medicines – national reserve supply of Augmentin and Erythromycin (both adult and child)
- Pacific nations requests to obtain supply from NZ
- NHCC have a technical advisory group to draw clinical advice from and looking at the potential surge requirements.

The group discussed the need to know what's going on ourselves – MD's and Peter to keep track daily and notify the team if there is a need to escalate. Susan to send through WHO link.

Discussed OIA – this is a whole of government response, nationally led through NHCC.

Action:

- 1) Peter to seek clarification from MoH as to what information they require from Pharmac contacts. Peter to link in with Scott and Greg.
- 2) Susan to send through WHO link.

Next meeting Tuesday 11am – agenda items:

- Team update – all
- Any actions

Ngā mihi

Gillian Anderson | Contract Manager/Team Leader | Procurement & Contracts
PHARMAC | PO Box 10 254 | Level 9, 40 Mercer Street, Wellington

section 9(2)(a) | P: +64 4 460 4990 | F: +64 4 460 4995 | www.pharmac.govt.nz

From: Gillian Anderson
Sent: Friday, 14 February 2020 12:21 PM
To: Section 9(2)(a)
Subject: what we sent to suppliers

Dear Suppliers

PHARMAC is aware that the recent outbreak of coronavirus and its impact on China, including disruption to transport and major distribution hubs, may have the potential to cause disruption to supplies of medicines and medical devices to New Zealand. We wish to assess the level of possible risk to the supply chain for any publicly funded medicines and devices.

Please provide a list of any funded medicines or medical devices you supply to the New Zealand market that have raw material or finished product manufactured in China, or pass through China en route to New Zealand. Please include your assessment of the level of supply risk for these products.

Should a supply disruption be anticipated, we will work closely with medicine and medical device companies, healthcare professionals and other authorities to determine an appropriate course of action.

The Ministry of Health is coordinating a national approach via the formation of the National Health Coordination Centre. We are working closely with them and will advise of any changes in demand and/or requirements if and when they occur.

Please provide this list to your PHARMAC Contract Manager by 20th February 2020.

Ngā mihi

Gillian Anderson | Contract Manager/Team Leader | Procurement & Contracts
PHARMAC | PO Box 10 254 | Level 9, 40 Mercer Street, Wellington
section 9(2)(a) | P: +64 4 460 4990 | F: +64 4 460 4995 | www.pharmac.govt.nz

RELEASED UNDER THE ACT
OFFICIAL INFORMATION ACT

From: section 9(2)(a)
Sent: Thursday, 13 February 2020 1:58 PM
To: Peter Yoo
Cc: Andrew Oliver; Brian Roulston; Craig Butler; section 9(2)(a)
Subject: RE: strategic implications of COVID-19

Thanks a lot.

This is likely to be edited but I will forward the meeting notes and your original draft to section 9(2)(a) so it is not lost.

section 9(2)(a)
 Public Health Physician
 Public Health Strategy and Advice
 Public Health
 Population Health and Prevention
 Ministry of Health

section 9(2)(a)

section 9(2)(a)

section 9(2)(a)

The Ministry of Health has recently updated its email address format to firstname.lastname@health.govt.nz. Currently any emails sent to the old email address format (firstname_lastname@moh.govt.nz) are being auto-forwarded. When the auto-forward service is switched off, senders using the old format will receive an 'undeliverable' message. Therefore, you may wish to update your contact details accordingly.

From: "Peter Yoo" section 9(2)(a)
To: section 9(2)(a)
Cc: "Brian Roulston" section 9(2)(a); "Craig Butler" section 9(2)(a); section 9(2)(a); "Andrew Oliver" section 9(2)(a)
Date: 13/02/2020 01:34 p.m.
Subject: RE: strategic implications of COVID-19

Hi section 9(2)(a)

Please find attached the document with tracked changes.


Please see below the minor amendments (in red) wrt to the flu vaccine meeting notes you sent us:

- *Flu vax production starts in October for Southern Hem. Will be closing down soon and will start the Northern Hem production*
- *PHARMAC have contacted their contracted supplier-little chance of additional vaccine*
- *One other supplier might be able to source more vaccine but not likely*
- *Constraint globally (can usually get from other markets but high demand possibly due to COVID-19)*
- *Expecting 1.5 mill doses for NZ-about two-thirds for over 65 years and immune comp. etc and rest private market.*
- *Any messaging is likely to increase the demand from the private market*
- *Maybe issues for NZ sourcing any new treatments as we are likely to be one of last countries needing these if we "keep it out" for longer than other countries*


Ngā mihi

Peter Yoo | Therapeutic Group Manager | Pharmaceutical Funding
PHARMAC | PO Box 10 254 | Level 12, 40 Mercer Street, Wellington
section 9(2)(a) | P: +64 4 460 4990 | F: +64 4 460 4995 | www.pharmac.govt.nz


Out of scope




Out of scope




Out of scope




Out of scope



Out of scope



Out of scope



PLEASE DO NOT RELEASE UNDER THE OFFICIAL INFORMATION ACT

FILE NOTE

Subject:	RE: strategic implications of COVID-19
Event Type:	Phone Call
Author:	Peter Yoo
Attendees:	Craig Butler, Brian Roulston
Location:	PHARMAC
Date event took place:	12 Feb 2020, 3:15pm

section 9(2)(a) got in touch with PHARMAC earlier this morning to discuss the below.

section 9(2)(a) is a public health physician, working for MoH/DPMC. DPMC wants to front foot the issue as they arise and wants to focus on what is being done currently.

We discussed the wording for the below draft. The highlighted section below may suggest that PHARMAC is aware of or has identified the antivirals and antibiotics used in managing cases of nCoV which is not true. Suggested re-wording this section.

Email from section 9(2)(a)

NZ is also dependent on an imported large number of pharmaceuticals and medical devices. PHARMAC is working with their suppliers to assess the possible impact on the supply chain including the impact on managing current stock on hand and future supply of pharmaceuticals and medical devices for the health sector. This includes the impacts of:

- Increased usage of antivirals and antibiotics in managing cases of nCoV
- Increased usage of devices and pharmaceuticals for ICU admissions
- Global transport disruptions from the closure of distribution centres
- Manufacturing or supply disruption for pharmaceuticals or medical devices where raw materials or finished product are sourced from China

We also pointed out that not all procurement of medical devices and critical products are managed by PHARMAC – others may be managed by DHBS, NZHP and others.

section 9(2)(a) will re-word and send to us for review.

section 9(2)(a) also asked about the potential situation with increased demand for flu vaccination. We responded that it is highly unlikely that we will be able to obtain more stock but we are exploring options.

- PHARMAC have contacted their contracted suppliers-little chance of additional vaccine
- One other supplier might be able to source more vaccine but not likely
- Constraint globally (can usually get from other markets but high demand possibly due to COVID-19)
- Usually have about 1.5 mill doses for NZ-about half for over 65 years and immune comp. etc and rest private market. Will need to find a solution to ensure the supply for the funded group
- Any messaging is likely to increase the demand from the private market

Lastly, we have reiterated that PHARMAC needs to be advised by the MoH of the treatment framework/regimen relating to 2019-nCoV cases.

From: Peter Yoo
Sent: Monday, 10 February 2020 5:00 PM
To: section 9(2)(a)
Subject: Re: Coronavirus 2019-nCoV

Dear section 9(2)(a)

Thank you for your call earlier this afternoon about coronavirus 2019-nCoV.

PHARMAC is currently monitoring the situation and is working closely with the National Health Coordination Centre (NHCC) Response Team at the Ministry of Health as the situation progresses.

The [Ministry of Health website](#) contains the latest information on the 2019-nCoV situation in New Zealand, including [information and resources for healthcare professionals](#). If needed, we suggest getting in contact with the Ministry of Health for any further clarification.

In regards to your query on the use of oseltamivir (Tamiflu) as an empirical treatment option for potential influenza cases, please be advised that oseltamivir (Tamiflu) is funded if the Special Authority criteria have been met ([RS1307](#)). PHARMAC does not have any information to advise on its effectiveness against the new type of coronavirus.

Again, I strongly encourage you to liaise with the NHCC Response Team at the Ministry of Health.

Please do not hesitate to contact me should you require any further information.

Ngā mihi

Peter Yoo | Therapeutic Group Manager | Pharmaceutical Funding
PHARMAC | PO Box 10 254 | Level 12, 40 Mercer Street, Wellington
section 9(2)(a) | P: +64 4 460 4990 | F: +64 4 460 4995 | www.pharmac.govt.nz

RELEASED UNDER THE ACT
OFFICIAL INFORMATION ACT

From: section 9(2)(a)
Sent: Wednesday, 5 February 2020 2:28 PM
To: Peter Yoo
Cc: Gillian Anderson; Andrew Oliver; section 9(2)(a)
 section 9(2)(a)
Subject: Fw: Coronavirus epidemic and pharmaceutical supply chain risk - meeting on Friday at 9am

Hi Peter

We are aware that there are some potential pressures on supply of some items required by the health sector as an impact of the novel coronavirus event.

When we meet on Friday morning, it would be useful to scope and discuss:

- potential supply chain disruption to critical items required by the NZ health sector, as an outcome of the situation in China (including pharmaceuticals and medical devices) and impacts
- additional impacts of any supply chain disruptions, if the health sector experienced a surge in demand for specific items (eg: from any domestic response to 2019-nCoV cases)

In terms of background for the meeting, the Ministry does maintain the national reserve supply of some critical clinical items that may be needed in a pandemic. A summary of the composition and volume of the National Reserve Supply is the Ministry website: <https://www.health.govt.nz/our-work/emergency-management/national-reserve-supplies/composition-national-reserve-supply>

On 4 February we sent out a request to DHB Emergency Managers for information on their supply of Personal Protective Equipment. We have asked if they could advise us by (5pm on Friday) if they have:

- sufficient stock available for the next four weeks to manage your **business as usual** usage requirements for: General purpose masks, P2 masks, aprons, gloves, eye protection, hand sanitiser
- Based on their current stock availability, what capacity they have to manage any surge in demand within the DHB over and above business as usual requirements (eg: if they had an increase in demand to the levels required during winter)
- confirming what additional capacity DHBs have in their locally held stock, which forms part of the overall national reserve supply
- asking if there are any specific pressures for their DHB on continuity of access to personal protective equipment in the short term.

I have asked section 9(2)(a) (Chief Medical Officer), section 9(2)(a) (Chief Advisor - Pharmacy), section 9(2)(a) (Chief Advisor - DHB Performance, Support & Infrastructure), section 9(2)(a) (Principal Advisor Public Health) and section 9(2)(a) (Senior Advisor - EMT) to also attend on Friday.

The meeting details are:

Friday 7 February @9am

Ministry of Health

Kind regards

section 9(2)(a)

section 9(2)(a)

Senior Advisor - Pandemic Readiness
Emergency Management
Population Health and Prevention
Ministry of Health

section 9(2)(k)

<http://www.moh.govt.nz>

mailto:section 9(2)(a)

From: "Peter Yoo" section 9(2)(a)
To: section 9(2)(a)
Cc: section 9(2)(a) "Andrew Oliver" section 9(2)(a) "Scott Metcalfe"
section 9(2)(a) "Gillian Anderson" section 9(2)(a) "Gregory Evans" section 9(2)(a)
Date: 04/02/2020 05:06 p.m.
Subject: Coronavirus epidemic and pharmaceutical supply chain risk

Dear NHCC Response Manager,

In light of recent developments with the international spread of 2019-nCoV, we are closely monitoring the situation and updates from the Ministry of Health.

Although the Ministry of Health has stated that the risk of an ongoing outbreak in New Zealand remains low, PHARMAC staff have identified a number of potential issues for continuity of supply of pharmaceuticals and medical devices that could arise as the international situation progresses.

Factors that may affect the continuity of supply include:

- Increased usage of antivirals and antibiotics in managing cases of nCoV
- Increased usage of devices and pharmaceuticals for ICU admissions
- Global transport disruptions from the closure of distribution centres such as Shanghai
- Manufacturing or supply disruption for pharmaceuticals or medical devices where raw materials or finished product are sourced from China

PHARMAC is working with pharmaceutical and medical device suppliers to assess the possible impact on the supply chain. However, we would be grateful for any insights from the Ministry into the risk assessment and planning that the NHCC is conducting or planning, especially in relation to the estimated impact on health resource utilisation, including increased pharmaceutical and medical device usage resulting from managing cases in community and DHB settings.

We look forward to hearing back from you

Ngā mihi

Peter Yoo | Therapeutic Group Manager | Pharmaceutical Funding
PHARMAC | PO Box 10 254 | Level 12, 40 Mercer Street, Wellington
section 9(2)(a) | P: +64 4 460 4990 | F: +64 4 460 4995 | www.pharmac.govt.nz

This email and any files transmitted with it are confidential and intended solely for the use of the individual or entity to whom they are addressed. If you have received this email in error please notify the system manager.
This footnote also confirms that this email message has been swept by MIMESweeper for the presence of computer viruses.
www.clearswift.com

Statement of confidentiality: This e-mail message and any accompanying attachments may contain information that is IN-CONFIDENCE and subject to legal privilege.

If you are not the intended recipient, do not read, use, disseminate,

Out of scope

Out of scope

Out of scope

Out of scope

From: "Peter Yoo" section 9(2)(a)
 To: section 9(2)(a)
 Cc: "Craig Butler" section 9(2)(a) "Lisa Williams" section 9(2)(a) "Sarah Fitt" section 9(2)(a)
 "Caroline De Luca" section 9(2)(a) "Geraldine MacGibbon" section 9(2)(a)
 Date: 12/02/2020 10:55 a.m.
 Subject: RE: strategic implications of N-Gov 2019

Good morning section 9(2)(a)

Thanks for the email.

Craig and I are free to take your call at 3:15pm this afternoon – does this suit you?

Ngā mihi

Peter Yoo | Therapeutic Group Manager | Pharmaceutical Funding
 PHARMAC | PO Box 10 254 | Level 12, 40 Mercer Street, Wellington
 section 9(2)(a) P: +64 4 460 4990 | F: +64 4 460 4995 | www.pharmac.govt.nz

From: section 9(2)(a)
Sent: Wednesday, 12 February 2020 10:18 am
To: Peter Yoo section 9(2)(a)
Subject: strategic implications of N-Cov 2019

Kia ora Peter,

I am part of a team working on a strategic estimate document to outline the possible strategic implications of the novel corona virus. I understand you met with section 9(2)(a) and others from the Ministry of Health last week. Based on the meeting we have drafted a section related to PHARMAC and would appreciate your review today if possible (see below). Please note this is an all of government response document so we are only outlining high level strategic issues so only summary points will be included.

I will also call you to see if we have missed any issues and to discuss the questions below. Feel free to call me if you are free.

Current wording in draft for review

NZ is also dependent on an imported large number of pharmaceuticals and medical devices. PHARMAC is working with their suppliers to assess the possible impact on the supply chain including the impact on managing current stock on hand and future supply of pharmaceuticals and medical devices for the health sector. This includes the impacts of:

- Increased usage of antivirals and antibiotics in managing cases of nCoV
- Increased usage of devices and pharmaceuticals for ICU admissions
- Global transport disruptions from the closure of distribution centres
- Manufacturing or supply disruption for pharmaceuticals or medical devices where raw materials or finished product are sourced from China

Information from suppliers is expected on 20 February 2020.

Questions for discussion

Are there any medical treatments/ supplies which we are only able to source from China and/or for which we do not have alternative arrangements?

Are there any conditions especially at risk and what support arrangements can be developed?

What are the implications of an increase in demand for influenza vaccine (either from public, or as a measure to ensure fewer hospital beds are occupied due to influenza and complications, if N-Cov 2019 is circulating in New Zealand)

Thanks for your help

I will be in touch today.

Nga mihi

section 9(2)(a)

section 9(2)(a)

Public Health Physician
Public Health Strategy and Advice
Public Health
Population Health and Prevention
Ministry of Health

section 9(2)(a)

section 9(2)(a)

From: Melody Willis on behalf of Gillian Anderson
Sent: Wednesday, 5 February 2020 1:53 PM
Subject: Coronavirus preparation and planning

Dear Suppliers

PHARMAC is aware that the recent outbreak of coronavirus and its impact on China, including disruption to transport and major distribution hubs, may have the potential to cause disruption to supplies of medicines and medical devices to New Zealand. We wish to assess the level of possible risk to the supply chain for any publicly funded medicines and devices.

Please provide a list of any funded medicines or medical devices you supply to the New Zealand market that have raw material or finished product manufactured in China, or pass through China en route to New Zealand. Please include your assessment of the level of supply risk for these products.

Should a supply disruption be anticipated, we will work closely with medicine and medical device companies, healthcare professionals and other authorities to determine an appropriate course of action.

The Ministry of Health is coordinating a national approach via the formation of the National Health Coordination Centre. We are working closely with them and will advise of any changes in demand and/or requirements if and when they occur.

Please provide this list to your PHARMAC Contract Manager by 20th February 2020.

Ngā mihi

Gillian Anderson | Contract Manager/Team Leader | Procurement & Contracts
PHARMAC | PO Box 10 254 | Level 9, 40 Mercer Street, Wellington
section 9(2)(a) | P: +64 4 460 4990 | F: +64 4 460 4995 | www.pharmac.govt.nz

RELEASED UNDER THE OFFICIAL INFORMATION ACT

From: Gillian Anderson
Sent: Tuesday, 4 February 2020 3:46 PM
To: Scott Metcalfe; Peter Yoo; Andrew Oliver; Jane Wright; Gregory Evans; Hannah Tibble-Gotz
Subject: Coordinated coronavirus response

Hi all,

Thanks for your time yesterday. It was a very constructive meeting!

We thought it would be a good idea to have a coordinated approach to gathering information and responding to the recent coronavirus outbreak. Primarily I was interested in ensuring we had

- consistent key messages
- a coordinated link into the Ministry of Health/National Health Coordination Centre
- identifying possible supply issues

Actions from the meeting were:

- Peter to draft up an email to send to the National Health Coordination Centre
- Gillian to draft message to go out to suppliers
- Scott to send links to Jane and Hannah
- Gillian to set up follow-up meeting in a weeks' time.

I'll pop this note into Objective as a file note if you are all happy with it.

Ngā mihi

Gillian Anderson | Contract Manager/Team Leader | Procurement & Contracts
PHARMAC | PO Box 10 254 | Level 9, 40 Mercer Street, Wellington
section 9(2)(a) | P: +64 4 460 4990 | F: +64 4 460 4995 | www.pharmac.govt.nz

RELEASED UNDER THE
OFFICIAL INFORMATION ACT

From: Scott Metcalfe
Sent: Tuesday, 4 February 2020 1:56 PM
To: Gillian Anderson; Peter Yoo; Andrew Oliver; Gregory Evans
Subject: RE: Coronavirus epidemic and risks to supply chains and liaison with Ministry of Health

Hi all – where have we got to with drafting something up for Ministry?
 Highlighting potential Rx and device needs, vulnerable stocks of specific treatments that might eventually be used (specific antivirals – see eg lopinavir/ritonavir speculation at <https://www.sciencemag.org/news/2020/01/can-anti-hiv-combination-or-other-existing-drugs-outwit-new-coronavirus>), and what is our sense of supply vulnerability for other medicines etc entirely manufactured in China, components produced there, or otherwise affected?; are we anticipating and slowdown now and ahead re Chinese and/or China-related imports affected by incoming flight bans or other things? (eg Chinese port closures with the epidemic, production slowdowns)

Ngā mihi
 Scott

Scott Springford-Metcalfe (was Scott Metcalfe) | Chief Advisor Population Medicine / Deputy Medical Director
 section 9(2)(a)
 section 9(2)(a)

From: Scott Metcalfe
Sent: Tuesday, 4 February 2020 10:35 AM
To: Jane Wright section 9(2)(a)
Cc: Gillian Anderson section 9(2)(a); Peter Yoo section 9(2)(a); Hannah Tibble-Gotz section 9(2)(a); Andrew Oliver section 9(2)(a); Gregory Evans section 9(2)(a)
Subject: RE: Coronavirus a coordinated approach

Hi Jane – oops I forgot to send you these links, which we and PHARMAC staff can keep updated on coronavirus epi (the key one of course being the first...)
<https://www.health.govt.nz/our-work/diseases-and-conditions/novel-coronavirus-2019-ncov>
<https://www.thelancet.com/coronavirus>
<https://www.nejm.org/coronavirus>
<https://www.who.int/emergencies/diseases/novel-coronavirus-2019>

Ngā mihi
 Scott

Scott Springford-Metcalfe (was Scott Metcalfe) | Chief Advisor Population Medicine / Deputy Medical Director
 section 9(2)(a)
 section 9(2)(a)

-----Original Appointment-----
From: Gillian Anderson section 9(2)(a)
Sent: Monday, 3 February 2020 8:23 AM
To: Peter Yoo; Brian Roulston; Hannah Tibble-Gotz; Scott Metcalfe
Cc: Andrew Oliver
Subject: Coronavirus a coordinated approach
When: Monday, 3 February 2020 1:30 PM-2:00 PM (UTC+12:00) Auckland, Wellington.
Where: Room - Burgess Level 12 – Seats 5-6

Just updating the time to be half an hour (I think this will be enough anyway) – I'm sorry I have been called to another meeting at 2pm!

Hi all,

We are starting to get a few queries coming through to all our various areas and thought it would be a good idea to have a coordinated approach to comms and planning.

If I've missed someone off or you'd like to delegate to someone else, please do.

Cheers,

Gillian

RELEASED UNDER THE
OFFICIAL INFORMATION ACT